MRK Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

117.260

Open

114.980

VWAP

116.16

Vol

8.32M

Mkt Cap

286.28B

Low

114.110

Amount

966.44M

EV/EBITDA(TTM)

10.55

Total Shares

2.47B

EV

321.11B

EV/OCF(TTM)

19.49

P/S(TTM)

4.47

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

Show More

Events Timeline

(ET)

2026-03-08

22:30:00

KKR Plans to Sell CoolIT Systems for Over $3B

2026-03-08

17:00:00

Dr. Vinay Prasad to Leave Agency at End of April

2026-03-03 (ET)

2026-03-03

08:40:00

Tempus AI and Merck Expand Collaboration for Precision Medicine

2026-03-01 (ET)

2026-03-01

11:40:00

Merck Presents Keytruda and Welireg Trial Results

2026-03-01

11:40:00

Merck and Eisai Announce Kidney Cancer Trial Results

2026-02-27 (ET)

2026-02-27

10:20:00

Merck's KEYTRUDA with Chemotherapy Significantly Improves Survival in Ovarian Cancer Patients

2026-02-27

10:10:00

Pfizer and Astellas Announce Positive Results for Bladder Cancer Treatment

2026-02-25 (ET)

2026-02-25

16:40:00

Merck Animal Health Receives FDA Approval for NUMELVI for Canine Allergic Dermatitis

2026-02-25

13:00:00

Merck Presents Phase 3 Results for HIV-1 Drug DOR/ISL

News

NASDAQ.COM

03-08NASDAQ.COM

Investment Comparison Between Eli Lilly and Merck

Fool

GLP-1 Drugs Boost Eli Lilly's Stock Price

Marketbeat

03-07Marketbeat

Three Overlooked Stocks That Are Too Inexpensive to Dismiss

CNBC

US-Israel Conflict Escalates, Pharma Stocks as Safe Haven

seekingalpha

03-06seekingalpha

Democratic Senators Question Pharma Price Deals with Trump Administration

Yahoo Finance

03-06Yahoo Finance

Dow Jones Futures Rise Slightly Ahead of Jobs Report

16 Analyst Rating

Wall Street analysts forecast MRK stock price to rise

11 Buy

5 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

95.00

Averages

119.53

High

139.00

Current: 0.000

Low

95.00

Averages

119.53

High

139.00

RBC Capital

Outperform

initiated

$142

AI Analysis

2026-02-24

Reason

RBC Capital

Price Target

$142

AI Analysis

2026-02-24

initiated

Outperform

Reason

RBC Capital initiated coverage of Merck with an Outperform rating and $142 price target. The firm sees the stock's investor enthusiasm continuing with near-term launches and Phase 3 readouts driving estimate upgrades. The Keytruda loss of exclusivity in late 2028 will be "de-risking" and management's a track record provides confidence in an early-2030s return to growth versus consensus which has Merck's erosion well into the mid-2030s, the analyst tells investors in a research note.

Barclays

Overweight

initiated

$140

2026-02-19

Reason

Barclays

Price Target

$140

2026-02-19

initiated

Overweight

Reason

Barclays initiated coverage of Merck with an Overweight rating and $140 price target. The firm says the company's 2026 will bring "first-in-class" launches and pivotal data readouts. Merck shares offer potential for both earnings upside and multiple expansion, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MRK

Unlock Now

Valuation Metrics

The current forward P/E ratio for Merck & Co Inc (MRK.N) is 12.32, compared to its 5-year average forward P/E of 16.97. For a more detailed relative valuation and DCF analysis to assess Merck & Co Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

16.97

Current PE

12.32

Overvalued PE

32.01

Undervalued PE

1.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

11.55

Current EV/EBITDA

8.86

Overvalued EV/EBITDA

16.67

Undervalued EV/EBITDA

6.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

4.07

Current PS

3.95

Overvalued PS

4.67

Undervalued PS

3.47

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what are the best stocks right now

Intellectia · 72 candidates

Region: USAnalyst Consensus: Strong Buy, Moderate BuyEps 5yr Cagr: >= 10Pe Ttm: 10 - 35Return On Equity: >= 15.0%Is Index Component: GSPC, NDX

Ticker

Name

Market Cap$

Charles Schwab Corp

166.86B

Gilead Sciences Inc

178.68B

NXP Semiconductors NV

50.98B

Williams Companies Inc

90.69B

Sysco Corp

40.82B

IQVIA Holdings Inc

29.29B

Which stock is best for investing $500

Intellectia · 65 candidates

Market Cap: >= 10.00BRegion: USPrice: $10.00 - $300.00Analyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 0Eps 5yr Cagr: >= 0Pe Ttm: 10 - 30Return On Equity: >= 10.0%Is Index Component: GSPCAnnual Eps Yoy Growth: >= 0.0%

Ticker

Name

Market Cap$

Coterra Energy Inc

23.90B

ONEOK Inc

54.24B

VICI Properties Inc

32.45B

Morgan Stanley

265.17B

Charles Schwab Corp

167.32B

Progressive Corp

125.08B

principales acciones que paguen dividendos

Intellectia · 96 candidates

Dividend Yield Ttm: 2 - 8Dividend Payout Ratio: 20.00 - 80.00Is Index Component: GSPCDividend 5yr Cagr: >= 0

Ticker

Name

Market Cap$

Exxon Mobil Corp

642.60B

Johnson & Johnson

599.00B

Home Depot Inc

369.15B

Coca-Cola Co

345.00B

Cisco Systems Inc

313.70B

Merck & Co Inc

300.17B

best stocks to swing trade

Intellectia · 1222 candidates

Region: USRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $-5.00 - $40.00Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Taiwan Semiconductor Manufacturing Co Ltd

1.94T

Exxon Mobil Corp

635.43B

Costco Wholesale Corp

448.66B

AbbVie Inc

410.36B

Procter & Gamble Co

390.70B

General Electric Co

358.95B

Stocks with same technicals as DHR

Intellectia · 52 candidates

Market Cap: >= 150.00BRegion: USRsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

NVIDIA Corp

4.31T

Apple Inc

3.88T

Alphabet Inc

3.77T

Broadcom Inc

1.52T

Tesla Inc

1.51T

Walmart Inc

1.02T

what stock should i buy today

Intellectia · 57 candidates

Market Cap: >= 20.00BRegion: USRevenue 5yr Cagr: >= 5Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Is Index Component: GSPCOne Month Predict Return: >= 0.0%

Ticker

Name

Market Cap$

EOG Resources Inc

64.99B

Monolithic Power Systems Inc

57.48B

American Electric Power Company Inc

71.45B

Sysco Corp

42.68B

Darden Restaurants Inc

24.74B

Atmos Energy Corp

30.38B

stock to increase price today and tomorrow

Intellectia · 116 candidates

Price Change Pct: >= $0.01Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 65One Day Predict Return: >= 1.0%

Ticker

Name

Market Cap$

PEDEVCO Corp

59.31M

First BanCorp

3.52B

Jerash Holdings (US) Inc

41.91M

Ryman Hospitality Properties Inc

6.43B

Kestrel Group Ltd

92.75M

Sify Technologies Ltd

1.08B

what best stock to buy right now??

Intellectia · 92 candidates

Market Cap: >= 20.00BNet Margin: >= 10.00Eps 5yr Cagr: >= 10Pe Ttm: 10 - 35List Exchange: XNYS, XNASIs Index Component: GSPC, NDX

Ticker

Name

Market Cap$

Charles Schwab Corp

169.48B

Booking Holdings Inc

137.64B

Gilead Sciences Inc

189.55B

NXP Semiconductors NV

59.73B

Kinder Morgan Inc

71.84B

Wells Fargo & Co

273.88B

give me top 5 screener

Intellectia · 62 candidates

Region: USMarket Cap Category: large, megaNet Margin: >= 10.00Eps 5yr Cagr: >= 10Pe Ttm: 10 - 35Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Alphabet Inc

3.70T

JPMorgan Chase & Co

823.62B

Johnson & Johnson

586.69B

Micron Technology Inc

463.33B

Bank of America Corp

379.02B

Caterpillar Inc

362.31B

Next best healthcare after LLY

Intellectia · 5 candidates

Market Cap: >= 50.00BSector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsNet Margin: >= 15.00Eps 5yr Cagr: >= 15Moving Average Relationship: PriceAboveMA200One Month Predict Return: >= 0.0%

Ticker

Name

Market Cap$

Johnson & Johnson

571.91B

Novartis

297.79B

AstraZeneca PLC

293.35B

Merck & Co Inc

291.20B

Eli Lilly and Co

993.46B

Whales Holding MRK

SAMA Foreign Holdings

Pacer Advisors, Inc.

Causeway Capital Management LLC

Thornburg Investment Management, Inc.

ALPS Advisors, Inc.

Journey Strategic Wealth LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Merck & Co Inc (MRK) stock price today?

The current price of MRK is 117.11 USD — it has increased 1.14

What is Merck & Co Inc (MRK)'s business?

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

What is the price predicton of MRK Stock?

Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is119.53 USD with a low forecast of 95.00 USD and a high forecast of 139.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Merck & Co Inc (MRK)'s revenue for the last quarter?

Merck & Co Inc revenue for the last quarter amounts to 16.40B USD, increased 4.97

What is Merck & Co Inc (MRK)'s earnings per share (EPS) for the last quarter?

Merck & Co Inc. EPS for the last quarter amounts to 1.19 USD, decreased -19.59

How many employees does Merck & Co Inc (MRK). have?

Merck & Co Inc (MRK) has 75000 emplpoyees as of March 09 2026.

What is Merck & Co Inc (MRK) market cap?

Today MRK has the market capitalization of 286.28B USD.